202 related articles for article (PubMed ID: 23883350)
21. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
22. FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques.
Martins WP; Vieira AD; Figueiredo JB; Nastri CO
Cochrane Database Syst Rev; 2013 Mar; (3):CD010042. PubMed ID: 23543584
[TBL] [Abstract][Full Text] [Related]
23. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin.
Grøndahl ML; Borup R; Lee YB; Myrhøj V; Meinertz H; Sørensen S
Fertil Steril; 2009 May; 91(5):1820-30. PubMed ID: 18439596
[TBL] [Abstract][Full Text] [Related]
24. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women.
Achrekar SK; Modi DN; Desai SK; Mangoli VS; Mangoli RV; Mahale SD
Fertil Steril; 2009 Feb; 91(2):432-9. PubMed ID: 18321487
[TBL] [Abstract][Full Text] [Related]
25. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome.
Kerkelä E; Skottman H; Friden B; Bjuresten K; Kere J; Hovatta O
Fertil Steril; 2007 Mar; 87(3):603-6. PubMed ID: 17074323
[TBL] [Abstract][Full Text] [Related]
26. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
27. In view of ovarian steroidogenesis and luteal construction to explore the effects of Bushen Huoxue recipe in mice of ovarian hyperstimulation.
Song Y; Hu R; Li F; Huang Y; Liu Z; Geng Y; Ding J; Ma W; Song K; Dong H; Zhang M
J Ethnopharmacol; 2024 Jan; 318(Pt A):116913. PubMed ID: 37479069
[TBL] [Abstract][Full Text] [Related]
28. Effect of controlled ovarian hyperstimulation on puberty and estrus in mice offspring.
Ding J; Tan X; Song K; Ma W; Xiao J; Zhang M
Reproduction; 2017 Oct; 154(4):433-444. PubMed ID: 28687593
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of the luteinizing hormone/chorionic gonadotropin receptor gene: association with maldescended testes and male infertility.
Simoni M; Tüttelmann F; Michel C; Böckenfeld Y; Nieschlag E; Gromoll J
Pharmacogenet Genomics; 2008 Mar; 18(3):193-200. PubMed ID: 18300940
[TBL] [Abstract][Full Text] [Related]
30. Is ovarian hyperstimulation associated with higher blood pressure in 4-year-old IVF offspring? Part I: multivariable regression analysis.
Seggers J; Haadsma ML; La Bastide-Van Gemert S; Heineman MJ; Middelburg KJ; Roseboom TJ; Schendelaar P; Van den Heuvel ER; Hadders-Algra M
Hum Reprod; 2014 Mar; 29(3):502-9. PubMed ID: 24365797
[TBL] [Abstract][Full Text] [Related]
31. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome.
Lee KH; Kim SH; Jee BC; Kim YJ; Suh CS; Kim KC; Lee WD
Fertil Steril; 2010 May; 93(7):2274-80. PubMed ID: 19249755
[TBL] [Abstract][Full Text] [Related]
33. Involvement of single nucleotide polymorphisms in ovarian poor response.
Ghaderian SMH; Akbarzadeh R; Salehpour S
J Assist Reprod Genet; 2021 Sep; 38(9):2405-2413. PubMed ID: 34050449
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
[TBL] [Abstract][Full Text] [Related]
35. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
36. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype.
Hanevik HI; Hilmarsen HT; Skjelbred CF; Tanbo T; Kahn JA
Gynecol Endocrinol; 2012 Nov; 28(11):845-9. PubMed ID: 22587628
[TBL] [Abstract][Full Text] [Related]
37. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Different Progestins in Women With Advanced Endometriosis Undergoing Controlled Ovarian Hyperstimulation for
Guo H; Li J; Shen X; Cong Y; Wang Y; Wu L; Li B; Gao H; Ma M; Zhang W; Mao X; Fu Y; Lyu Q; Chai W; Kuang Y
Front Endocrinol (Lausanne); 2020; 11():129. PubMed ID: 32265834
[No Abstract] [Full Text] [Related]
39. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization.
Aramwit P; Pruksananonda K; Kasettratat N; Jammeechai K
Am J Health Syst Pharm; 2008 Jun; 65(12):1148-53. PubMed ID: 18541685
[TBL] [Abstract][Full Text] [Related]
40. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?
Altmäe S; Hovatta O; Stavreus-Evers A; Salumets A
Hum Reprod Update; 2011; 17(6):813-28. PubMed ID: 21862569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
